OBESITY PILL Archives - European Biotechnology Magazine

Tag Archive for: OBESITY PILL

Oral GLP-1 receptor agonists are the next big thing in weight management. However, gastrointestinal side effects caused by the high doses required for oral administration remain a challenge to be addressed.

Lilly’s weight loss pill orforglipron meets primary Phase III endpoint

Eli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met the primary endpoint of its registration study and is set to be submitted for approval in the United States.